Life Science Analytics, March 2008, Pages: 190
"Autoimmune And InflammationInflammation " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company
Select Biosciences Ltd, Feb 2009, Pages: 310
for apoptosis modulators in cancer, CNS diseases, and chronic inflammation/autoimmunity.
- Gain up-to-date competitive intelligence on apoptosis-modulating pipelines and identify the most promising drugs under
La Merie, Nov 2010, Pages: 22
Antagonist R&D Pipelines 1. IL-1/R Antagonist
- IL-1 and IL-1R Antagonists in autoimmune & Inflammation
- IL-1 and IL-1R Antagonists in Metabolism
- IL-1 and IL-1R Antagonists in Pulmonary & Respiratory
Life Science Analytics, March 2008, Pages: 79
"Autoimmune And InflammationAutoimmuneDiseases " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company
Jain PharmaBiotech, Feb 2012, Pages: 276
This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric
Life Science Analytics, March 2008, Pages: 117
"Autoimmune And Inflammation Arthritis " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage
Life Science Analytics, March 2008, Pages: 315
"Autoimmune And Inflammation Rheumatoid Arthritis " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company
Business Insights, Jan 2010, Pages: 106
opportunities to gain access to further orphan indications which have a similar disease mechanism.
Key findings from this report
- The developers of orphan drugs receive several incentives from the governments
Biophoenix Limited, Feb 2009, Pages: 312
modulators in cancer, CNS diseases, and chronic inflammation/autoimmunity. - Gain up-to-date competitive intelligence on apoptosis-modulating pipelines and identify the most promising drugs under development
Jain PharmaBiotech, Feb 2012, Pages: 864
STEMPRO? EZChek? for analysis of biomarkers of hESCs
SSEA-4 as biomarker of MSCs
Gaseous mediators as biomarkers of disease
Autoantibodies as biomarkers of autoimmunediseases
Comparison of various
Life Science Analytics, March 2008, Pages: 164
"Autoimmune And Inflammation Transplant Rejection or Transplantation " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy
Life Science Analytics, March 2008, Pages: 191
"Autoimmune And Inflammation Allergy" contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage
Business Insights, May 2009, Pages: 335
companies. This report identifies areas of innovation and opportunity for kinase targeting drugs in cancer and examines the non-cancer applications of kinase drugs across inflammatory and autoimmunediseases
Life Science Analytics, March 2008, Pages: 79
"Autoimmune And Inflammation Lupus " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage
GBI Research, Dec 2010, Pages: 198
such as cancer, inflammation, diabetes and rheumatoid arthritis, as well as major biosimilars in the drug classes erythropoietin, insulin analogs and human growth hormones The report also gives insights
La Merie, Jan 2009, Pages: 21
processes including inflammation and autoimmunity.
The report includes a compilation of current active projects in research and development of subtype-selective and multi-PKC inhibitors as well as of PKC
Espicom Business Intelligence Ltd, Nov 2007, Pages: 614
intelligence - has published The Pharma R&D Fact Book 2007.
This essential report examines the research investment and drugpipelines for 39 leading companies from Abbott and Alcon to UCB and Wyeth. A complete
Global Markets Direct, Nov 2011, Pages: 44
Description
Mechanism of Action
R&D Progress
Ilaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Inflammation And AutoimmuneDiseases - Drug Profile
La Merie, Nov 2010, Pages: 26
molecules. In addition, the report lists company-specific S1P R&D pipelines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action
